CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE Sample Clauses

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE a public scientific and technological establishment, whose registered office is located at 0, xxx Xxxxxx-Xxxx - 75794 Paris Cedex 16 - France, whose intra-community VAT number is FR40180089013, with SIRET number 180089013 04033, code NAF 7219Z, represented by its Chairman, Xx Xxxxx XXXXX, duly authorised for the purposes hereof, hereinafter referred to as “CNRS”, And
Sample 1Sample 2Sample 3
AutoNDA by SimpleDocs
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE. A scientific and technological public establishment, Located at 0, xxx Xxxxxx-Xxxx, F-75794 Paris Cedex 16, Hereinafter referred to as « CNRS » Each referred to below individually as « the Party » and collectively as « the Parties ». PREAMBULE Effective Date: …… / …… /…… In the frame of an agreement and considering the nature of the present Agreement, CNRS gave mandate to the UNISTRA to sign alone in its own name and on behalf of CNRS. UNISTRA exercises this mandate by entrusting the linked activities to Conectus, which is expressly accepted by CNRS. Conectus is dedicated to the management of the contracting activities, budget execution, intellectual property and the technology transfer of any research laboratories placed under UNISTRA controls. Within a national French program of huge investments in the public research, UNISTRA and CNRS (hereinafter referred to as « Establishments ») accompanied the creation of the Technology Transfer Acceleration Company (SATT) Conectus, owning shares in the company. Conectus is dedicated to the management of the contracting activities, the budget execution, the intellectual property and the technology transfer of UNISTRA on an exclusive basis and get a full delegation to sign all agreements. In order to evaluate the opportunity of a collaboration, the Parties decide to exchange Information as defined below. Each Party agrees that the Partner may communicate Information, as defined below, to its affiliated companies, which means any Party who controls, directly or not, the Party, is controlled by the Party or was under the same control as the Party as considered in article L233-3 of the French code de commerce. The academic laboratory involved is: ……………………………………………………………………………………………………………………………………………… (Full name) ……………………………… (Initials) ……………………………… (Unit number) The Parties decide to sign the present Agreement in order to secure their discussions requiring confidential Information relating to the following subject: ………………………………………………………..……………………………………………………………………………………………………………. ……………………………………………………………………..………………………………………………………………………………………………. ………………………………………………………..……………………………………………………………………………………………………………. ………………………………………………………..……………………………………………………………………………………………………………. PARTIES AGREE AS FOLLOWS : The confidential information, hereinafter referred to as « Information », include all information or data, whatever the form and including, without limitation, all written or printed documents, all samples, models, methods ...
Sample 1Sample 2
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE. CNRS will participate in the KM3NeT-PP project though IN2P3, which is responsible for coordinating the national research program in fundamental particle, nuclear and astroparticle physics. It comprises 18 research laboratories working in close collaboration with the French university system. The following IN2P3 laboratories will join the KM3NeT preparatory phase: Centre de Physique des Particules de Marseille (CPPM), the Institut Pluridisciplinaire Xxxxxx Xxxxxx (IPHC) in Strasbourg and the Laboratoire AstroParticule et Cosmologie (APC) in Paris. CNRS will co-coordinate the work packages WPB, WPC1, WPC2, WPC3 as well as make important contributions to all of the other work packages except WPA. CNRS participates to KM3NeT-PP with a third party called “Université de la Méditerranée Aix- Marseille 2.
Sample 1
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE. A public institution of a scientific and technological nature (EPST) Hereinafter: the CNRS Registered office: 3, Xxx Xxxxxx-Xxxx — 70000 XXXXX CEDEX 16
Sample 1
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE. (CNRS): - Université Paris Sud (member of Laboratoire de Chimie Physique (UMR8000-LCP)
Sample 1
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE. CNRS FRANCE INNOVATION SCIENTIFIQUE ET TRANSFERT (FIST) SA, a Public Company
Sample 1

Related to CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

  • Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

  • Clinical Development Licensee will have sole responsibility for and sole decision making over the clinical development of any Product arising from the Research Program in the Field. Notwithstanding the foregoing, if Licensee wishes to conduct clinical development of a Development Candidate at Penn and Penn has the clinical expertise, interest and ability to run such a trial as assessed at Penn’s sole discretion, such a study will be conducted under a separate Clinical Trial Agreement to be negotiated by the Parties prior to initiation of such study. Such separate clinical trial agreement will include a detailed clinical development plan, including costs and time lines for conducting the Clinical Trial.

  • Business Development Company Buyer is a business development company as defined in Section 202(a)(22) of the Investment Advisors Act of 1940.

  • Manufacturing and Marketing Rights The Company has not granted rights to manufacture, produce, assemble, license, market, or sell its products to any other person and is not bound by any agreement that affects the Company's exclusive right to develop, manufacture, assemble, distribute, market, or sell its products.

  • Research Independence The Company acknowledges that each Underwriter’s research analysts and research departments, if any, are required to be independent from their respective investment banking divisions and are subject to certain regulations and internal policies, and that such Underwriter’s research analysts may hold and make statements or investment recommendations and/or publish research reports with respect to the Company and/or the offering that differ from the views of its investment bankers. The Company hereby waives and releases, to the fullest extent permitted by law, any claims that the Company may have against such Underwriter with respect to any conflict of interest that may arise from the fact that the views expressed by their independent research analysts and research departments may be different from or inconsistent with the views or advice communicated to the Company by such Underwriter’s investment banking divisions. The Company acknowledges that the Representative is a full service securities firm and as such from time to time, subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short position in debt or equity securities of the Company.

  • Joint Marketing After receiving Xxxxxxxx’s advance written approval, which will not be unreasonably withheld, SHIFT4 may list and announce Merchant as a user of SHIFT4’s service, but will make public announcements of Merchant’s use or describe Xxxxxxxx’s use of service only for marketing purposes.

  • Initial Development Plan Not later than the Effective Date, Licensee shall have provided Merck with an initial Development plan for the Licensed Product in the Field in the Territory, which shall be incorporated as part of this Agreement as Attachment 3.02(a) (as may be amended in accordance with this Agreement, the “Development Plan”). **CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

  • Research and Development (i) Advice and assistance in relation to research and development of Party B;

  • Business Development Company Status The Company, during a period of at least 12 months from the Closing Time, will use its commercially reasonable efforts to maintain its status as a business development company; provided, however, the Company may cease to be, or withdraw its election as, a business development company, with the approval of the board of directors and a vote of stockholders as required by Section 58 of the 1940 Act or any successor provision.

  • Cornerstone shall notify the LLC and confirm such advice in writing (i) when the filing of any post-effective amendment to the Registration Statement or supplement to the Prospectus is required, when the same is filed and, in the case of the Registration Statement and any post-effective amendment, when the same becomes effective, (ii) of any request by the Securities and Exchange Commission for any amendment of or supplement to the Registration Statement or the Prospectus or for additional information and (iii) of the entry of any stop order suspending the effectiveness of the Registration Statement or the initiation or threatening of any proceedings for that purpose, and, if such stop order shall be entered, Cornerstone shall use its best efforts promptly to obtain the lifting thereof.

Time is Money Join Law Insider Premium to draft better contracts faster.